- Home
- USGO vs XGN Comparison
USGO vs XGN Comparison
Compare USGO & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | USGO | XGN |
|---|---|---|
| Founded | 2015 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medical Specialities |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.1M | 110.7M |
| IPO Year | 2023 | 2014 |
Fundamental Metrics
Financial Performance| Metric | USGO | XGN |
|---|---|---|
| Price | $8.16 | $7.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $30.75 | $8.86 |
| AVG Volume (30 Days) | 78.6K | ★ 261.5K |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 19.12 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $8.12 |
| Revenue Next Year | N/A | $13.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.16 | $2.59 |
| 52 Week High | $17.98 | $12.23 |
Technical Indicators
Market Signals| Indicator | USGO | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 41.47 | 51.76 |
| Support Level | $7.44 | $4.08 |
| Resistance Level | $8.39 | $7.99 |
| Average True Range (ATR) | 0.48 | 0.38 |
| MACD | -0.14 | -0.13 |
| Stochastic Oscillator | 6.08 | 3.84 |
Price Performance
Historical ComparisonAbout USGO U.S. GoldMining Inc.
US Goldmining Inc is a mineral exploration company with a focus on the exploration and development of a project located in Alaska, USA. The company's primary asset is the 100%-owned Whistler exploration property located in Alaska, USA. It operates and reports in one segment, which focuses on the exploration and development of mineral properties.
About XGN Exagen Inc.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.